Video

Dr. Schaider Discusses Drug Resistance for Melanoma

Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

According to Schaider, adaptive drug resistance occurs at the beginning of treatment. Drug resistance generally occurs in the first 3 to 6 weeks.

More studies need to be conducted to determine why the cells become resistant to certain treatments, states Schaider.

Related Videos
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma
Leo I. Gordon, MD
Janaki Neela Sharma, MD, University of Miami
Richard Kim, MD, Moffitt Cancer Center
Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.